Received Aug 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Guillain Barre syndrome; There is also a period of time that she does not remember; This serious case was reported by a consumer via call center representative and described the occurrence of guillain barre syndrome in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of vaccine on an unknown date). On 23-AUG-2024, the patient received the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced guillain barre syndrome (Verbatim: Guillain Barre syndrome) (serious criteria hospitalization and GSK medically significant) and memory loss (Verbatim: There is also a period of time that she does not remember). The outcome of the guillain barre syndrome and memory loss were unknown. It was unknown if the reporter considered the guillain barre syndrome and memory loss to be related to Shingrix. The company considered the guillain barre syndrome to be unrelated to Shingrix. It was unknown if the company considered the memory loss to be related to Shingrix. Additional Information: GSK Receipt Date: 12-AUG-2025 Reporter was the patient who received her second dose of Shingrix on 23rd August 2024. She stated that she was hospitalized from October 2024 to November 2024. She was diagnosed with Guillain Barre syndrome. She could not walk and stand at that time. There was also a period that she did not remember. Today (on the day reporting) she still cannot walk, she cannot put on her shoes, and was in a long term care facility.; Sender's Comments: A case of Guillain-Barre syndrome, an unknown time after receiving Shingrix, in a 63-year-old female patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow up has not been received.